The Dynamics of SARS-CoV-2 (RT-PCR) Testing

Area of Science:

• Virology
• Infectious Diseases
• Molecular Diagnostics

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, led to the rapid deployment of in vitro diagnostic tests under Emergency Use Authorization (EUA).
• The Department of Health and Human Services (HHS) activated the EUA to facilitate the development and accessibility of diagnostic testing for SARS-CoV-2.
• Initial SARS-CoV-2 RT-PCR tests showed high agreement rates, but were developed using artificially doped samples.

Observation:

• Despite high reported agreement rates, SARS-CoV-2 RT-PCR tests approved under the COVID-19 EUA lack clinical sensitivity and specificity.
• These molecular detection assays were developed and validated using in vitro analyses with artificially doped SARS-CoV-2 RNA samples, not clinical "gold standard" specimens.
• The absence of a clinical gold standard for diagnosis poses challenges for interpreting RT-PCR results.

Findings:

• This study presents three complex patient cases that highlight the challenges in interpreting results from the latest generation of SARS-CoV-2 RT-PCR molecular detection assays.
• Cautious interpretation is advised due to the limitations in clinical applicability of current RT-PCR tests.
• Providers face significant challenges in managing patients with potential SARS-CoV-2 infections due to diagnostic assay limitations.

Implications:

• The findings underscore the critical need for clinically validated diagnostic standards for SARS-CoV-2 testing.
• Healthcare providers must exercise caution when interpreting RT-PCR results, especially in ambiguous cases.
• Further research is necessary to establish reliable "gold standard" methods for accurate COVID-19 diagnosis and patient management.